Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $51.45

AnaptysBio, Inc. (NASDAQ:ANAB) has been given an average rating of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $45.09.

ANAB has been the topic of a number of recent analyst reports. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Guggenheim dropped their price target on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday. Wedbush reissued an “outperform” rating and set a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday. JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Finally, UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th.

AnaptysBio Stock Up 3.8 %

Shares of AnaptysBio stock opened at $15.59 on Thursday. AnaptysBio has a 52-week low of $14.20 and a 52-week high of $41.31. The company has a market capitalization of $474.40 million, a P/E ratio of -2.56 and a beta of -0.11. The company has a 50 day moving average of $25.56 and a 200 day moving average of $29.43.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, research analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other news, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the transaction, the insider now owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. The trade was a 55.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This represents a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Frazier Life Sciences Management L.P. boosted its stake in shares of AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after buying an additional 1,265,891 shares in the last quarter. FMR LLC grew its stake in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after purchasing an additional 438,557 shares during the period. Jennison Associates LLC purchased a new position in shares of AnaptysBio in the 3rd quarter valued at about $8,874,000. Victory Capital Management Inc. lifted its stake in shares of AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after buying an additional 168,813 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.